Vikas Lifecare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
VIKASLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vikas Lifecare reported H1 FY26 revenue of ₹22,967 Lakhs, up 3.5% YoY from ₹22,192 Lakhs in H1 FY25. However, the profit surge to ₹12,415 Lakhs (vs ₹199 Lakhs) is almost entirely due to a one-time gain of ₹13,030 Lakhs from the Ebix UK settlement, not operational performance. The Q2 standalone quarter (July-Sep 2025) showed a loss of ₹349 Lakhs. The company restated Q1 (April-June 2025) figures: profit revised from -280 Lakhs to 12,764 Lakhs due to recognition of the Ebix settlement gain and foreign exchange adjustments. The auditors issued an unmodified review report but highlighted four emphasis-of-matter items: (1) the Ebix UK acquisition with pending regulatory approvals, (2) restatement of Q1 results, (3) related party transactions lacking shareholder approval as required under SEBI LODR, and (4) pending investment in IGL Genesis Technologies (IGTL) not accounted for. Tax implications from the Ebix settlement remain unrecognised pending expert opinions. Total assets grew to ₹80,524 Lakhs with investments surging to ₹47,249 Lakhs (vs ₹4,841 Lakhs) reflecting the Ebix UK stake valued at ₹42,841 Lakhs.
The profit looks impressive at ₹12,415 Lakhs but is almost entirely driven by a one-time settlement gain; underlying Q2 operations are loss-making. The restatement raises questions about financial controls. Unapproved related party transactions and pending regulatory clearances on the Ebix deal create compliance risk. Shareholders should carefully review the postal ballot for related party transaction approvals.